EP1200072A2 - Method of treating psychotic disorders - Google Patents

Method of treating psychotic disorders

Info

Publication number
EP1200072A2
EP1200072A2 EP00926982A EP00926982A EP1200072A2 EP 1200072 A2 EP1200072 A2 EP 1200072A2 EP 00926982 A EP00926982 A EP 00926982A EP 00926982 A EP00926982 A EP 00926982A EP 1200072 A2 EP1200072 A2 EP 1200072A2
Authority
EP
European Patent Office
Prior art keywords
formula
compounds
alkyl
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00926982A
Other languages
German (de)
French (fr)
Inventor
Roelof Van Hes
Johannes A. M. Van Der Heijden
Cornelis G. Kruse
Stephen K. Long
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Healthcare Products BV
Original Assignee
Solvay Pharmaceuticals BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals BV filed Critical Solvay Pharmaceuticals BV
Priority to EP00926982A priority Critical patent/EP1200072A2/en
Publication of EP1200072A2 publication Critical patent/EP1200072A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • EP 0830864 describes a method for treating a patient suffering from or susceptible to psychosis, acute mania, mild anxiety states, or depression in combination with psychotic episodes by administering to said patient an effective amount of a first component which is an atypical antipsychotic, in combination with an effective amount of a second component which is a serotonin reuptake inhibitor.
  • Such compounds show activity as antagonists at dopamine D 2 receptors as they potentially antagonize apomorphine-induced climbing behaviour in mice.
  • the compounds also show activity as inhibitors of serotonin reuptake, as they potentiate 5-HTP induced behaviour in mice.
  • Preferably used compounds have hy-values of less than 10 nanomolair in the receptor binding assays for D 2 antagonistic activity and serotonin reuptake inhibitory activity.
  • antipsychotics e.g. the conditioned avoidance response; Van der Heijden & Bradford, Behav. Brain Res., 1988, 31 :61-67
  • antidepressants or anxiolytics e.g. suppression of stress-induced vocalization; van der Poel et al., Psychopharmacology, 1989, 97: 147- 148.
  • the inhibitory activity of serotonin reuptake inherent in these compounds may be responsible for the therapeutic effects observed in behavioural models sensitive to either antidepressants or anxiolytics.
  • the invention is illustrated by means of a group of 3-tetrahydropyridin 4-yl indoles having a combination of a high affinity for the dopamine D 2 receptor and the serotonin reuptake site, but is not restricted to the use of these compounds.
  • R is halogen, CF 3 , alkyl (1-3C), alkoxy (1-3C), CN or SCH 3 - m the value 0, 1 or 2
  • R 2 is H or alkyl (1-3C)
  • - n has the value 3, 4, 5 or 6 - R 3 is halogen, alkyl (1-4C) or alkoxy (1-4C)
  • R 4 represents H, C ⁇ -alkyl, C ⁇ -alkoxy or CN
  • R 5 is H, halogen, C ⁇ -alkyl, C ⁇ -alkoxy, CN, NH 2 , SO 2 -alkyl (1-3C), NO 2 or SO 2 NH 2
  • t has the value 1-3
  • Q is a group of the formula ii-vi
  • Pharmacologically acceptable acids with which the compounds of the invention can form suitable acid addition salts are for example hydrochloric acid, sulphuric acid, phosphoric acid, nitric acid, and organic acids such as citric acid, fumaric acid, maleic acid, tartaric acid, acetic acid, benzoic acid, p-toluene sulphonic acid, methanesulphonic acid and naphthalene sulphonic acid.
  • the compounds are their acid addition salts can be brought into forms suitable for administration by means of suitable processes using auxiliary substances such as liquid and solid carrier materials.
  • the compounds having formula (I) can be obtained as follows: a) by reaction of a compound of formula (II)
  • A represents the group -(CH 2 ) n . CN, to the corresponding group -(CH 2 ) ⁇ -NH 2 ;
  • Reaction step b (ii) can be carried out for example in organic solvents such as tetrahydrofuran and toluene at reflux temperature.
  • the starting compounds as used in method a) of the formula (II) can be obtained in a manner known per se by reacting an optionally substituted indole derivate with 4- piperidone.
  • the starting compounds used in method b) having formula (IV) can be obtained by reaction of a compound having formula (II) with a bromoalkyl nitrile of the formula Br-(CH 2 ) n . 1 -CN in a manner known per se.
  • the compounds having formula (la) wherein Q is the group of formula (a) can be obtained by reacting an amine obtainable according to the above method b (i) with the appropriate benzoyl chloride.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to the use of compounds having both dopamine D2-antagonistic activity and serotonin reuptake inhibitory (SRI) activity for the treatment of psychotic disorders such as schizophrenia. The invention further relates to a group of novel (1, 2, 3,6-tetrahydropyridin-4-yl) indole and -furan derivatives having these activities.

Description

Method of treating psychotic disorders
The invention relates to the use of compounds having combined dopamine D2- antagonistic activity and serotonin reuptake inhibitory activity for the preparation of pharmaceutical compositions for the treatment of psychotic disorders such as schizophrenia.
It is described in J. Clin, Psychopharmacol, (1998) vol 18, no.1 , p. 2-9 and (1998), vol. 18, no.3, p.208-211 that there is considerable evidence that adding selective serotonin reuptake inhibitor (SSRI) to antipsychotic treatment improves negative symptoms of schizophrenia.
EP 0830864 describes a method for treating a patient suffering from or susceptible to psychosis, acute mania, mild anxiety states, or depression in combination with psychotic episodes by administering to said patient an effective amount of a first component which is an atypical antipsychotic, in combination with an effective amount of a second component which is a serotonin reuptake inhibitor.
It has now been found that compounds having affinity for both the dopamine D2 receptor and the serotonin reuptake site are particularly useful for the treatment of psychotic disorders such as schizophrenia. Such compounds allow for a more complete treatment of all disease symptoms (e.g. positive symptoms and negative symptoms). Such compounds can be used also in patients suffering from mania, anxiety or depression in combination with psychotic episodes.
Such compounds show activity as antagonists at dopamine D2 receptors as they potentially antagonize apomorphine-induced climbing behaviour in mice. The compounds also show activity as inhibitors of serotonin reuptake, as they potentiate 5-HTP induced behaviour in mice.
Preferably used compounds have hy-values of less than 10 nanomolair in the receptor binding assays for D2 antagonistic activity and serotonin reuptake inhibitory activity.
These compounds are active in therapeutic models sensitive to clinically relevant antipsychotics (e.g. the conditioned avoidance response; Van der Heijden & Bradford, Behav. Brain Res., 1988, 31 :61-67) and antidepressants or anxiolytics (e.g. suppression of stress-induced vocalization; van der Poel et al., Psychopharmacology, 1989, 97: 147- 148).
in contrast to clinically relevant dopamine D2 receptor antagonists these compounds have a low propensity to induce catalepsy in rodents and as such are likely to induce less extrapyramidal side effects than existing antipsychotic agents.
The inhibitory activity of serotonin reuptake inherent in these compounds may be responsible for the therapeutic effects observed in behavioural models sensitive to either antidepressants or anxiolytics.
The combination of two desired types of activity into one molecule has a number of advantages in view of combining two different active components in a composition: 1. constant ratio of both activities due to one kinetic behaviour
2. less burden for the body of the patient with chemical compounds
3. less possibilities for undesired side-effects
4. no interaction between active components.
The invention is illustrated by means of a group of 3-tetrahydropyridin 4-yl indoles having a combination of a high affinity for the dopamine D2 receptor and the serotonin reuptake site, but is not restricted to the use of these compounds.
The group of 3-tetrahydropyridin-4-yl indole derivatives of the formula (I):
wherein:
- R, is halogen, CF3, alkyl (1-3C), alkoxy (1-3C), CN or SCH3 - m the value 0, 1 or 2
- R2 is H or alkyl (1-3C)
- n has the value 3, 4, 5 or 6 - R3 is halogen, alkyl (1-4C) or alkoxy (1-4C)
- p has the value 0, 1 , or 2 and salts thereof, show high affinity both for the dopamine D2-receptor and the serotonin reuptake site. This group of compounds is described in patent application no. WO 99/EP/07912.
Preferred compounds of the invention are compounds having formula (I) wherein R, hydrogen (i.e. m=0) or F, Cl, CH3 or CN, and m=1 , R2 is H or CH3, n=4, R3 is hydrogen (i.e. p=0), or F or alkyl (1-4C), p=1, and the salts thereof.
The invention is further illustrated by means of a group of novel compounds having the general formula
wherein (R m and R2 have the above meanings, q has the value 2-4, and Q is a group of the formula
wherein R4 represents H, C^-alkyl, C^-alkoxy or CN, R5 is H, halogen, C^-alkyl, C^-alkoxy, CN, NH2, SO2-alkyl (1-3C), NO2 or SO2NH2, and t has the value 1-3, or Q is a group of the formula ii-vi
iii iv v vι wherein Re is H or C^-alkyl, and R7 is H or OH, or the general formula (lb)
wherein (R^)m has the above meanings and Q^ represents a group of the formula (i)
and salts thereof.
A preferred compound of this group of novel compounds is the compound of formula (la) wherein (R1)rn=5-F, R2=H, q=4 and Q is the group of the formula (iii), and the salts thereof.
Pharmacologically acceptable acids with which the compounds of the invention can form suitable acid addition salts are for example hydrochloric acid, sulphuric acid, phosphoric acid, nitric acid, and organic acids such as citric acid, fumaric acid, maleic acid, tartaric acid, acetic acid, benzoic acid, p-toluene sulphonic acid, methanesulphonic acid and naphthalene sulphonic acid.
The compounds are their acid addition salts can be brought into forms suitable for administration by means of suitable processes using auxiliary substances such as liquid and solid carrier materials.
The compounds having formula (I) can be obtained as follows: a) by reaction of a compound of formula (II)
with a compound of the formula (III)
wherein the symbols have the above meanings and L is a so-called leaving group, for example bromo. This reaction is carried out in a solvent such as acetonitrile in the presence of triethylamine or K2CO3 and Kl at reflux temperature, or b) by (i) reduction of the cyano group in a compound of formula (IV)
wherein A represents the group -(CH2)n. CN, to the corresponding group -(CH2)π-NH2; and
(ii) reacting the obtained amine with an optionally substituted phthalic anhydride of the formula (V)
in which formula the symbols have the meanings give above.
Reaction step b (i) can be carried out for example with LiAIH4 in an organic solvent such as tetrahydrofuran at reflux temperature.
Reaction step b (ii) can be carried out for example in organic solvents such as tetrahydrofuran and toluene at reflux temperature. The starting compounds as used in method a) of the formula (II) can be obtained in a manner known per se by reacting an optionally substituted indole derivate with 4- piperidone.
The starting compounds used in method b) having formula (IV) can be obtained by reaction of a compound having formula (II) with a bromoalkyl nitrile of the formula Br-(CH2)n.1-CN in a manner known per se.
The compounds having formula (la) wherein Q is the group of formula (a) can be obtained by reacting an amine obtainable according to the above method b (i) with the appropriate benzoyl chloride.
The compounds having formula (la) wherein Q represents a group of the formula i-vi can be prepared according to the above method a), i.e. reaction of a compound having formula (II) with a compound of the formula
L-(CH2)q-Q.
The preparation of the compounds having formula (I) and (la) will now be described in more detail in the following Examples.
Example I
Preparation of 1-methyl-3-(1 ,2,3,6-tetrahydropyridin-4-yl)indole.
To a solution of 4-piperidone.H2O.HCI (50 g , 0.32 mol) in 100 ml of acetic acid and 150 ml of trifluoroacetic acid was added dropwise a solution of 1-methylindole (11.5 ml, 0.09 mol) in 100 ml of acetic acid at room temperature. After stirring for 1h the reaction mixture was concentrated (in vacuum , temp. ca. 30°C), water was added , the mixture was made basic with potassium carbonate and extracted with ethyl acetate. The organic layer was separated, dried and purified by silica gel column chromatography (dichloromethane/methanol/ammonium hydroxide = 84/15/1 ) to give 9 g (47%) of the title compound. Example 2
Preparation of 5-fiuoro-3-(1 ,2,3,6-tetrahydropyridin-4-yl)indole.
To a solution of sodium (60 g , 2.6 mol) in 1000 ml of methanol was added 5- fluoroindole (49 g, 0.36 mol) and 4-piperidone.H2O.HCI (170 g , 1.11 mol). The mixture was heated under reflux for 18h , then concentrated , water was added and extracted with ethyl acetate. The combined organic layer was dried over sodium suifate and then concentrated. The resulting solid was dissolved in methanol (about 200 ml) and then diluted with water (about 1000-1500 ml). The precipitate was collected, washed with water and petroleum ether and then dried in a vacuum oven at 60°C. Yield 74 g (95%) of a yellow solid.
Example 3
Preparation of N-[4-[4-[(5-fluoro-1 H-indol-3-yl)-1 ,2,3,6-tetrahydropyridin-1-yl]butyl]- phthalimide.HCI (compound 1).
A solution of 5-fluoro-3-(1 ,2,3,6-tetrahydropyridin-4-yl)indole (7.5 g , 34.7 mmol) , N- (4-bromobutyl)phthalimide (10.8 g, 38.3 mmol) , triethylamine (4.5 ml) and potassium iodide (5.5 g) in 150 ml of acetonitrile was heated under reflux for 18h. The reaction mixture was concentrated and purified by silica gel column chromatografy
(dichloromethane/methanol /ammonium hydroxide= 92/7.5/0.5) to give 8.3 g of the title compound as a free base. Mp. 186°C. The hydrochloride was prepared by dissolving the above mentioned free base in 20 ml of 1M HCI in ethanol. The solution was concentrated and the resulting solid was washed with ether. Yield 8.4 g (54%) of compound 1 , mp. 224°C (dec).
Example 4
Preparation of 5-fluoro-3-[1-(3-cyanopropyl)-1 ,2,3,6-tetrahydropyridin-4-yl]indole.
A solution of 5-fluoro-3-(1 ,2,3,6-tetrahydropyridin-4-yl)indole (10 g , 46 mmol) , 4- bromobutyronitrile(5.6 ml , 56 mmol) , potassium carbonate (6.3 g) and potassium iodide (7.6 g) in 100 ml of acetonitrile was heated under reflux for 18h. The mixture was filtered and the residue on the filter was washed with dichloromethane/methanol/ammonium hydroxide = 84/15/1. The organic layer was concentrated to give 10.9 g (83%) of the title compound. M.p 152°C.
Example 5 Preparation of 5-fluoro-3-[1-(4-aminobutyl)-1 ,2,3,6-tetrahydropyridin-4-yl]indole.
To a solution of 5-fluoro-3-[1-(3-cyanopropyl)-1 ,2,3,6-tetrahydropyridin-4-yl]indole (10 g, 35 mmol) in 300 ml of dry THF was added slowly LiAIH4 (2.0 g ). The mixture was stirred and heated to reflux for 2h. Then the reaction mixture was cooled and water (1.9 ml) in THF (10 ml) was added slowly, followed by 2N sodium hydroxide (1.9 ml) . This mixture was heated to reflux for 0.25h , filtered over hyflo and concentrated to give 8.76 g (88%) of the title compound.
Example 6 Preparation of N-[4-[4-(5-fluoro-1 H-indol-3-yl)-1 ,2,3,6-tetrahydropyridin-1 -yl]butyl]-4- fluorophthalimide (compound 19).
To a solution of 5-fluoro-3-[1-(4-aminobutyl)-1 ,2,3,6-tetrahydropyridin-4-yl]indole (1.46 g, 5 mmol) in 20 ml of THF was added 4-fluorophthalic anhydride and 50 ml of toluene. The THF was removed by distillation and the resulting mixture was heated to reflux for 18h, with azeotropic removal of water (Dean and Stark apparatus). The reaction mixture was concentrated and purified by silica gel column chromatografy (dichloromethane/methanol/amrnonium hydroxide =92/7.5/0.5) to give 1.52 g (69%) of the title compound 19. M.p. 197-199°C.
According to method a) as illustrated in Examples 1-3, or method b) as illustrated in Examples 4-6 the compounds listed in the following Table 1 have been prepared: Table 1
Example 7
Λ/-[2-[4-[(7-methyl-1 H-indol-3-yl)-1 ,2,3,6-tetrahydropyridin-1 -yl]ethyl]-4- chlorobenzamid (compound 34) To a stirred solution of 7-methyl-3-[1-(2-aminoethyl)-1 ,2,3,6-tetrahydropyridin-4-yl] indole (1.5g, 6 mmol) in 30 ml THF was added potassium carbonate (0.8g) and para- chloro-benzoyl chloride (0.8 ml). After stirring was continued for 30 minutes, dichloromethane (100 ml) and water (50 ml) were added. The organic layer was washed with water, dried and concentrated in vacuo to give the title compound as a yellow powder (1.3g, 56%). M.p. 176-181 °C
Example 8
a) 4-chlorobutyl-Λ/-4-(3H)-quinazolinon A mixture of isatoicacid anhydride (5g, 31 mmol), 4-hydroxy-butylamine (2.7g) and triethylformiate (5.6 ml) was heated at 130°C for 1 hour. The mixture was concentrated in vacuo to a dark brown oil, which could be used in the next step without further purification. The oil was dissolved in anhydrous acetonitril (50 ml) and to this solution was added thionylchloride (4.5ml, 61 mmol). The reaction mixture was heated at 80°C for two hours giving a light brown precipitate. The mixture was cooled to room temperature and the title compound was isolated by filtration in a yield of 6.3 g, 80%; m.p. 162°C
b) 3-[4-[4-(5-fluoro-1 H-indol-3-yl)-1 ,2,3,6-tetrahydropyridin-1 -yl]-butyl]-4-(3H)- quinazolinon (compound 38)
To a stirring solution of 5-fluoro-3-[1 ,2,3,6-tetrahydropyridin]-indole (1.5g, 7 mmol) in acetonitril (50 ml) was added potassium carbonate (1.0g), potassium iodide (1.2 g) and 4-chloro-butyl-4-(3H)-quinazolinon (1.8g, 7.6 mmol). The mixture was refluxed for 60 hours, after which time TLC showed complete conversion. The solution was concentrated in vacuo on silica gel and the title compound was obtained as a yellow solid after flash chromatography. Yield: 1.6g, 55%; m.p. 168-170°C.
The compounds 27 to 44 indicated in tables 2 and 3 were prepared in a similar manner: Table 2 (formula la)
Table 3 (formula lb^

Claims

Claims
1. Use of a compound having combined dopamine D2-antagonistic activity and serotonin reuptake inhibitory activity for the preparation of pharmaceutical compositions for the treatment of psychotic disorders such as schizophrenia.
2. Use as claimed in claim 1 , characterised in that compounds having Ki-values of less than 10 nanomolair in the receptor binding assays for D2-antagonistic activity and serotinin reuptake inhibitory activity are used.
3. Compounds having formula (la) or (lb)
wherein R is halogen, CF3, alkyl (1-3C), alkoxy (1-3C), CN or SCH3, m has the value 0, 1 or 2, R2 is H or alkyl (1-3C), q has the value 2, 3 or 4, and Q is a group of the formula (a)
wherein R4 is H, alkyl (1-3C), alkoxy (1-3C)2 or CN, R5 is H, halogen, alkyl (1-3C), alkoxy (1-3C), CN, NH2, SO2-alkyl (1-3C), NO2 or SO2NH2) and t has the value 1 ,2 or 3, or Q is a group of the formula (ii-vi)
wherein R6 is H or alkyl (1-3C), and R7 is H or OH, and Q^ is a group of the formula (i),
I wherein R6 has the above meaning, and salts thereof.
4. Compound as claimed in claim 3 having formula (la) wherein (R^^δ-F, R2=H, q=4, and Q is the group (iii) wherein R6=H, and salts thereof.
5. Pharmaceutical compositions which contain at least one compound as claimed in claim 3 as an active component.
EP00926982A 1999-05-12 2000-04-14 Method of treating psychotic disorders Withdrawn EP1200072A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP00926982A EP1200072A2 (en) 1999-05-12 2000-04-14 Method of treating psychotic disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP99201524 1999-05-12
EP99201524 1999-05-12
EP00926982A EP1200072A2 (en) 1999-05-12 2000-04-14 Method of treating psychotic disorders
PCT/EP2000/003506 WO2000069424A2 (en) 1999-05-12 2000-04-14 Method of treating psychotic disorders

Publications (1)

Publication Number Publication Date
EP1200072A2 true EP1200072A2 (en) 2002-05-02

Family

ID=8240207

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00926982A Withdrawn EP1200072A2 (en) 1999-05-12 2000-04-14 Method of treating psychotic disorders

Country Status (5)

Country Link
EP (1) EP1200072A2 (en)
JP (1) JP2002544223A (en)
AU (1) AU4552200A (en)
CA (1) CA2373855A1 (en)
WO (1) WO2000069424A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR028685A1 (en) 2000-06-14 2003-05-21 Lundbeck & Co As H INDOL DERIVATIVES
DE102004023632A1 (en) * 2004-05-10 2005-12-08 Grünenthal GmbH Substituted cyclohexylcarboxylic acid derivatives
DE102004023506A1 (en) * 2004-05-10 2005-12-01 Grünenthal GmbH Chain-extended substituted cyclohexyl-1,4-diamine derivatives
DE102004023501A1 (en) * 2004-05-10 2005-12-01 Grünenthal GmbH Oxo-substituted cyclohexyl-1,4-diamine derivatives
DE102004023507A1 (en) * 2004-05-10 2005-12-01 Grünenthal GmbH Substituted cyclohexylacetic acid derivatives
DE102004023508A1 (en) * 2004-05-10 2005-12-08 Grünenthal GmbH Acid derivatives of substituted cyclohexyl-1,4-diamine
DE102004023522A1 (en) * 2004-05-10 2005-12-01 Grünenthal GmbH Substituted cyclohexyl-1,4-diamine derivatives
DE102004023635A1 (en) * 2004-05-10 2006-04-13 Grünenthal GmbH Heteroaryl-substituted cyclohexyl-1,4-diamine derivatives
JP2008521771A (en) * 2004-11-26 2008-06-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Isoxazoline-indole derivatives having improved antipsychotic and anxiolytic activity
US7371769B2 (en) 2004-12-07 2008-05-13 Solvay Pharmaceuticals B.V. Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
EP1828168A2 (en) * 2004-12-07 2007-09-05 Solvay Pharmaceuticals B.V. Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-d2 receptors and serotonin reuptake sites
US8101619B2 (en) 2004-12-08 2012-01-24 Solvay Pharmaceuticals B.V. Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124332A (en) * 1991-01-28 1992-06-23 Warner-Lambert Company Substituted indoles as central nervous system agents
CA2091204C (en) * 1992-03-11 1997-04-08 Ronald J. Mattson Antiischemic-piperazinyl and piperidinyl-cyclohexanes
DE4414113A1 (en) * 1994-04-22 1995-10-26 Merck Patent Gmbh 3-indolylpiperidines
DE19500689A1 (en) * 1995-01-12 1996-07-18 Merck Patent Gmbh Indole piperidine derivatives
AR004229A1 (en) * 1995-11-06 1998-11-04 Wyeth Corp INDOLALKYL DERIVATIVES OF BENZODIOXANMETILAMINA AND ITS USE TO PREPARE MEDICINES
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
ZA9711376B (en) * 1996-12-20 1998-07-21 Lundbeck & Co As H Indole or dihydroindole derivatives
AR020773A1 (en) * 1998-10-16 2002-05-29 Duphar Int Res COMPOUND DERIVED FROM 3- (TETRAHYDROPIRIDIN-4-IL) INDOL, METHOD TO PREPARE IT, A PHARMACEUTICAL COMPOSITION CONTAINING THEM, METHOD TO PREPARE SUCH COMPOSITION AND USE OF THE COMPOUND

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0069424A2 *

Also Published As

Publication number Publication date
CA2373855A1 (en) 2000-11-23
AU4552200A (en) 2000-12-05
WO2000069424A2 (en) 2000-11-23
JP2002544223A (en) 2002-12-24
WO2000069424A3 (en) 2001-06-07

Similar Documents

Publication Publication Date Title
US5834493A (en) Indole derivatives as 5-HT1A and/or 5-HT2 ligands
JPH0285277A (en) 1-indolylalkyl-4-(substituted pyridinyl)piperazine
JPWO2006123725A1 (en) Pyrrolidine derivative or its salt
EP0666258A1 (en) Indolylcycloaklanylamin- und Indolylcycloalkenylamine derivatives, their preparation and their use as anti-migraine agents
EP1200072A2 (en) Method of treating psychotic disorders
JPH11302279A (en) Novel piperazine and piperidine compound
RU2136678C1 (en) N-substituted 3-azabicyclo[32,0]heptane derivatives
RU2222535C2 (en) 3-tetrahydropyridine-4-ylindoles for treatment of psychotic disorders
JP2004517826A (en) Isoquinoline derivatives useful in treating CNS disorders
FI94863B (en) Process for the preparation of therapeutically useful halo-3,4-dihydrobenzothiopyranylamines
KR20010006587A (en) New cyano-indole serotonin-reuptake inhibitor compounds, a process for their preparation and pharmaceutical compositions containing them
WO2008033513A1 (en) ISOXAZOLINE ALPHA 1a/1d ADRENORECEPTOR ANTAGONISTS
WO1998042710A1 (en) Dihydropyrazino [1,2-a-]indole-1-one derivatives, preparation and application thereof in therapeutics
JP2008523028A (en) Benzodioxane piperazine derivatives having a combination of affinity for dopamine-D2 receptor and serotonin reabsorption site
MXPA01003882A (en) 3-tetrahydropyridin-4-yl indoles for treatment of psychotic disorders
FR2773800A1 (en) New 1,2-disubstituted benzimidazole derivative serotoninergic receptor antagonists, used for treating central nervous system, gastrointestinal, cardiovascular and respiratory disorders
JPS6197283A (en) Piperidine derivative, manufacture and medicinal composition
HK1039333B (en) 3-tetrahydropyridin-4-yl indoles for treatment of psychotic disorders
CN101072770A (en) Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
HK1109622A (en) Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-d2 receptors and serotonin reuptake sites

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011212

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT PAYMENT 20011212;LV PAYMENT 20011212;MK;RO PAYMENT 20011212;SI PAYMENT 20011212

17Q First examination report despatched

Effective date: 20040426

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040907